Final analysis, 454 patients with high-risk HER2-positive early breast cancer: adding atezolizumab to pertuzumab, trastuzumab and chemotherapy did not significantly improve secondary endpoints 3-year EFS (91.4% vs 89.0%; HR 0.90) or DFS. More adjuvant AEs (59.4% vs 47.0%).
RCTn = 454
Huober et al. Atezolizumab plus pertuzumab, trastuzumab, and chemotherapy in HER2-positive early breast cancer: final results of the phase III IMpassion050 trial